ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza

While most pathogens infect via mucosal surfaces, most current vaccines are delivered by injection. This situation remains despite awareness of the potential benefits of mucosal delivery for inducing protection against mucosa-infecting pathogens. A major obstacle to the development of such vaccines...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Hum Vaccin Immunother
Prif Awduron: Timothy, Andrea A, Tokanovic, Ana, Snibson, Kenneth J, Edwards, Stirling J, Pearse, Martin J, Scheerlinck, Jean-Pierre Y, Sutton, Philip
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2015
Pynciau:
INFLUENZA/Research Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514340/
https://ncbi.nlm.nih.gov/pubmed/25692970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21645515.2014.990859
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg